Medical-Fish-Skin Company Kerecis Expands Silicone Fish-Skin Combination Product Range for Surgical and Trauma Wound with SurgiClose® Silicone
Kerecis, the company pioneering the use of sustainably sourced fish skin and fatty acids in cellular therapy and tissue regeneration and protection, today announced the availability of SurgiClose® Silicone, which combines a fish-skin graft and silicone backing for efficient treatment of surgical and trauma wounds.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241227975454/en/
SurgiClose® Silicone (Photo: Business Wire)
SurgiClose® Silicone is a part of the SurgiClose® product family, which is intact fish-skin intended for the management of trauma wounds and surgical wounds in the operating room. The new product is available in two variations, SurgiClose® Silicone Adhesive with borders that overlap the fish-skin underneath and SurgiClose® Silicone Standard with non-overlapping borders.
“Applying Kerecis fish-skin to a surgical or trauma wound is a multi-step process that often requires supporting products such as sutures, staples, surgical tapes, contact layers, and wound-dressings. The new SurgiClose® Silicone product combines the fish-skin with a silicone-contact layer and thus eliminates the need for one of the supporting products. This makes the workflow in the surgical theater simpler and more cost effective,” said Fertram Sigurjonsson, Kerecis Founder and CEO.
About Kerecis
Kerecis, founded by Fertram Sigurjonsson, develops fish skin and fatty acid products for cellular therapy, tissue regeneration, and protection. When grafted onto damaged human tissue or implanted, the patented material supports the body’s own processes to heal and regenerate. Because no disease-transfer risk exists between cold-water fish and humans, the Kerecis fish-skin is only gently processed and retains its similarity to human tissue. The gentle processing preserves the skin’s original three-dimensional structure, maintaining its inherent natural strength, complexity, and molecules (such as fatty acids). Clinical studies show that Kerecis products heal wounds faster than competitors. Kerecis is the only global manufacturer of medical devices containing intact fish-skin and is the fastest growing company in the U.S. biologics skin market. Products include SurgiBind®/SuriClose®, GraftGuide®, MariGen®, and Shield™ for various medical applications. Committed to the UN Sustainable Development Goals, Kerecis uses sustainable Icelandic fish processed with renewable energy. Kerecis is a part of Coloplast, a leading supplier of intimate healthcare products. For more information, visit https://www.kerecis.com.
Trademarks and registered trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241227975454/en/
Contacts
Media Relations Agency
(952) 697 5220
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Multi-Mission Beechcraft King Air Demonstrator Unveiled at Paris Air Show16.6.2025 09:30:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, announced its new multi-mission Beechcraft King Air demonstration aircraft will be making its show and European debut at the 2025 Paris Air Show. The aircraft is equipped to showcase a wide range of missions available on the versatile and reliable Beechcraft King Air platform, and will be on static display Monday, June 16, through Thursday, June 19, at the Textron Pavilion A2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250615940392/en/ From Wichita, Kansas to Paris, France: Beechcraft King Air demonstrator makes international debut “The King Air’s acquisition and operation cost, combined with excellent speed, range and payload capacity make it an excellent value for a wide range of special missions,” said Bob Gibbs, vice president, Special Missions Sales. “The best-selling turboprop serves as an ideal platform for intelligence, surveillance and reconnaissance, ut
Ant International Announces Sustainability Framework, Serving 100 mn Merchants to Advance Inclusive Growth in Re-globalisation16.6.2025 08:00:00 EEST | Press release
Ant International, a leading global digital payment, digitisation and financial technology provider, today announced its Sustainability Framework in its first independent Sustainability Report. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250615891282/en/ Ant International announces Sustainability Framework in its Inaugural Sustainability Report A New Chapter of Growth with New Mission and Vision at a Critical Moment 2024 is a transformative year for Ant International, which became independent after a reorganisation of Ant Group. With headquarters in Singapore and over 30 offices around the world, Ant International provides cross-border digital payment, commerce and finance solutions to merchants and financial institutions, connecting 100 million+ merchants to global consumers across its 4 business units: global e-wallet gateway service (Alipay+), merchant payment service (Antom), cross-border business account service (Wor
Cosmetics Industry Icon Leonard A. Lauder, Chairman Emeritus, The Estée Lauder Companies, Passes Away15.6.2025 19:54:00 EEST | Press release
It is with deep sadness that The Estée Lauder Companies Inc. (NYSE: EL) announces that Chairman Emeritus Leonard A. Lauder passed away on June 14, at the age of 92, surrounded by family. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250615313230/en/ Leonard A. Lauder Mr. Lauder was born in 1933 in New York City, the oldest son of Estée and Joseph H. Lauder, the founders of The Estée Lauder Companies. He was a graduate of the Bronx High School of Science, the University of Pennsylvania’s Wharton School, and the Officer Candidate School of the United States Navy. Mr. Lauder studied at Columbia University’s Graduate School of Business. He served as a lieutenant in the U.S. Navy and as a Navy reservist, for which the U.S. Navy Supply Corps Foundation later recognized him with its Distinguished Alumni Award. He formally joined Estée Lauder in 1958, and for more than six decades, Mr. Lauder was a visionary and an innovator, helpi
Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA202515.6.2025 10:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced the first clinical data from two studies evaluating the safety, tolerability and efficacy of INCA033989, a novel, first in class, Incyte-discovered, targeted monoclonal antibody in patients with mutant calreticulin (mutCALR)-expressing myeloproliferative neoplasms (MPNs). These data – featured today in the Late-Breaking Oral Session (#LB4002) at the European Hematology Association 2025 (EHA2025) Congress in Milan, Italy – focus on the dose escalation portion of thestudies in patients with high risk essential thrombocythemia (ET) who are resistant/intolerant to prior cytoreductive therapy. The studies evaluated the safety and efficacy of INCA033989 in patients with ET as measured by hematologic response and reduction in mutCALR variant allele frequency (VAF). Results as of April 4, 2025, showed rapid and durable normalization of platelet counts across all dose levels, with a trend toward improved responses in higher doses (>400 mg), in patients with
Perma-Pipe International Holdings, Inc. Announces First Quarter Fiscal 2025 Financial Results13.6.2025 16:14:00 EEST | Press release
Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the first quarter ended April 30, 2025. “Sales for the first quarter were $46.7 million, resulting in an increase of $12.4 million, or 36.2%, compared to $34.3 million in the same quarter last year. Net income attributable to common stock of $5.0 million was an increase of $3.6 million, or 243%, compared to $1.4 million in the first quarter of the prior year,” noted President and CEO Saleh Sagr. Backlog currently stands at $131.1 million, a decrease of $7.0 million, compared to $138.1 million at January 31, 2025. However, the Company has experienced a significant increase in backlog of $68.0 million, or 108%, compared to $63.1 million at April 30, 2024. We feel encouraged with the level of backlog we have obtained, which remains more than double the level of reported backlog at the end of the first quarter last year,” Mr. Sagr continued. “Our first quarter results represent unprecedented perfor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom